Does Medicare Cover CombiPatch? 5 Formularies Checked and 2026 Costs

Does Medicare cover CombiPatch? For a regular pharmacy prescription, Original Medicare Parts A and B generally do not pay. A standalone Part D plan or Medicare Advantage plan with drug coverage may cover it if its current formulary lists the exact product. In five 2026 plan documents we checked, four listed CombiPatch and one marked it non-formulary.

By The HRT Index Editorial Team · Last verified: August 2026

Editorial research — not medically reviewed by a clinician. Educational only, not medical advice. Our medical review policy →

This page contains no paid provider recommendation. Affiliate disclosure →

The HRT Index is not affiliated with or endorsed by Medicare or the U.S. government.

So the real answer is not yes or no. It is which plan do you have?

And here is the damaging admission most coverage pages avoid: we cannot give you one honest national CombiPatch copay or tell you what percentage of Medicare plans cover it. Nobody publishes a complete current figure we could verify. We will not invent one.

This page is for you if: you are on Medicare, you take or were just prescribed CombiPatch, and a price or pharmacy rejection blindsided you.

This page is not for you if: you are deciding whether CombiPatch is medically right for you, or you want to change your dose, schedule, or product without your prescriber. That is a clinical decision, not a coverage decision.

What you have	Bottom line for a regular CombiPatch prescription	Your first move
Original Medicare only — Parts A and B	Usually not the pharmacy-benefit pathway for a patch you apply yourself	Check whether you also have standalone Part D or other drug coverage
Standalone Part D plan	May cover it; the plan’s current formulary controls	Check the exact strength, tier, restrictions, and pharmacy
Medicare Advantage with drug coverage	May cover it under that plan’s Part D benefit	Use that plan’s current drug list and pharmacy network
Employer or retiree drug plan	Coverage may come through Part D, additional employer coverage, or both	Ask which benefit is paying and whether the spending counts under Part D
Extra Help	A covered brand prescription can cost no more than $12.65 at a participating pharmacy in 2026	Confirm formulary coverage, then verify your Extra Help level
Covered inpatient stay	Part A generally includes drugs used as part of covered inpatient treatment	This does not decide coverage for your next retail refill

Your fastest first move: check CombiPatch in Medicare Plan Finder, then call the plan and pharmacy with your exact strength. Medicare Plan Finder is the official tool, and The HRT Index earns nothing from the link.

The HRT Index is the independent decision resource for online menopause and HRT care — comparing telehealth providers on clinical legitimacy, care quality, medication fit, price transparency, and access, with every claim verified and dated, so women can choose the path that fits their situation before their first consult.

---

Does Medicare Cover CombiPatch Under Part A, Part B, or Part D?

For a regular pharmacy fill, CombiPatch is ordinarily a Part D question. Part B covers a limited group of outpatient drugs and usually covers medicines a patient would not typically administer herself; Part D covers many outpatient prescriptions Part B does not. Part A may include drugs used during a covered inpatient stay, but that does not establish coverage for a later retail prescription.

Medicare’s own coverage guidance separates the parts this way:

Setting	Medicare pathway	What it means for CombiPatch
You apply the patch at home and fill it at a retail or mail pharmacy	Part D or Medicare Advantage with drug coverage	The exact plan formulary, pharmacy network, tier, and restrictions decide coverage
The drug is supplied as part of covered inpatient treatment	Part A	It may be included in the stay; this does not carry over to a retail refill
A clinician administers a qualifying outpatient drug	Part B in limited circumstances	This is not the ordinary pathway for a self-applied CombiPatch prescription

The practical mistake is showing a Medicare card at the pharmacy and assuming Parts A and B include a broad retail-drug benefit. They do not. If you have Original Medicare, look for a separate Part D card or confirm whether an employer or retiree plan supplies drug coverage.

Source: Medicare — outpatient prescription drug coverage and Medicare — how Part D drug plans work.

---

Why Can’t Anyone Tell You Exactly What CombiPatch Will Cost With Medicare?

No website can give every Medicare beneficiary one accurate CombiPatch copay. Your amount depends on the plan’s negotiated price, formulary tier, deductible, coverage stage, pharmacy status, quantity, and whether you receive Extra Help. A national number without those inputs is not your price.

We are going to be blunt about our own limits, because this is where coverage pages quietly cheat.

We could not verify a credible national figure for how many Medicare plans cover CombiPatch. We also could not verify one national Medicare copay. So we are not publishing either.

*We cannot tell you how much from the word “Medicare” alone. We can show you whether a specific document lists it, what restrictions appear, which 2026 cost rules apply, and exactly what to do if the answer is no.*

Your price can change because of all six of these:

Cost lever	The question that changes your answer
Formulary status	Is the exact CombiPatch product listed at all?
Tier	Is it preferred, non-preferred, or on another plan-defined tier?
Deductible	Does your plan apply a deductible to this tier, and have you met it?
Coverage stage	Are you in the deductible, initial-coverage, or catastrophic stage?
Pharmacy	Is the pharmacy in-network, and is it preferred?
Assistance	Do you receive Extra Help or another program that changes cost-sharing?

In 2026, no Part D plan may charge a deductible above $615. Out-of-pocket spending on covered Part D drugs reaches the catastrophic stage at $2,100, after which the member pays $0 for covered Part D drugs for the rest of the calendar year. Some plans have no deductible, and cash purchases made outside the Part D claim do not automatically count toward that threshold.

Source: Medicare — 2026 Part D costs and coverage stages.

---

Which Medicare Plans Actually Cover CombiPatch in 2026?

Coverage varies by plan, and the variation is real. In The HRT Index’s five-document 2026 spot-check, CombiPatch appeared on Tier 3 in two documents, Tier 4 in two, and as non-formulary in one. Two documents applied quantity limits, one attached a high-risk-medication advisory, and one marked the drug eligible for an extended supply.

The HRT Index 2026 CombiPatch Formulary Spot-Check

Official 2026 plan document	CombiPatch result	Tier	Restriction or code shown	Document date	What it means for a member
BCBS Michigan — Medicare Plus Blue Group PPO / Prescription Blue Group PDP	Listed	4	Quantity limit: 24 patches per 84 days	Updated August 1, 2026	The drug is listed, but the plan limits the covered quantity in that period
UnitedHealthcare Group Medicare Advantage	Listed	3	HRM	Last updated October 1, 2025 for the 2026 formulary	That document defines HRM as a high-risk-medication advisory for people 65 and older; it is not an automatic denial
AmeriHealth Medicare PPO, New Jersey	Non-formulary	—	NF	Updated June 23, 2026	It is not on the ordinary drug list; the member or prescriber may still request an exception
Independence / IBX — Keystone 65 Rx and Personal Choice 65 Rx	Listed	4	No row-specific restriction shown	Updated June 23, 2026	It is listed, but the member’s actual amount still depends on benefit stage and pharmacy
Pharmacy Benefit Dimensions PDP	Listed	3	Quantity limit: 8 patches per 28 days; EDS	Updated August 1, 2026	EDS means the drug may be available as an extended 90-day supply through a participating retail or mail-order pharmacy; plan terms still control

What this proves: two women with Medicare can call their plans on the same afternoon and hear completely different answers. You are not missing something. The system genuinely does this.

What this does not prove: nothing here supports a sentence such as “80% of Medicare plans cover CombiPatch.” Five documents selected to test real variation are not a national sample. We will not publish a percentage we did not earn.

How we checked: on August 3, 2026, we searched the official plan documents for CombiPatch and recorded the displayed tier, restriction code, quantity limit, and document date. A formulary row is evidence that the drug appears in that document; it is not a guarantee that a particular claim will be paid.

The quantity-limit detail worth noticing

The two limits are mathematically equivalent:

• 24 patches per 84 days
• 8 patches per 28 days

Both match the current continuous-combined label schedule of one replacement every three to four days—eight patches in a 28-day cycle. That is enough for the labeled schedule, but it leaves no spare patch in the limit. The label says that if a patch falls off, the same patch may be reapplied or a new one may be used while the original schedule continues. A replacement could therefore create a quantity-limit question at the next fill.

Your plan is the answer that matters. Run the CombiPatch Medicare coverage check →

The right online HRT provider isn't the same for every woman — it depends on your symptoms, your age and whether you have a uterus, your medication route preference (patch, pill, gel, or vaginal estrogen), your risk history, your insurance or cash-pay situation, and your state. Some situations belong with an in-person clinician first. Because a general answer can't resolve those for you, use The HRT Index's Find My HRT Path tool to match your situation to the right provider — and to flag when online care isn't the right starting point — before your first consult.

---

Is There a Generic Version of CombiPatch?

No. As of August 3, 2026, FDA’s current Orange Book records show CombiPatch under NDA 020870 and no approved ANDA generic equivalent. FDA issued revised product-specific guidance in February 2026 describing how a company could develop a generic transdermal product, but guidance is not an approval and does not create a product a pharmacist can dispense.

This matters more on Medicare than it does on most pages about price, because “ask for the generic” is usually the first savings instruction. For CombiPatch, that call goes nowhere.

FDA record	What it establishes	What it does not establish
Orange Book	CombiPatch is an approved brand product under NDA 020870; no approved ANDA equivalent was identified in the current records checked	That a generic is on sale
February 2026 product-specific guidance	FDA describes the evidence it expects from a future generic applicant	An approval, launch date, price, or available generic prescription

You cannot buy a generic CombiPatch. Neither can your pharmacist.

Where the confusion comes from

There are FDA-approved oral estradiol/norethindrone acetate products and generic oral tablets. Those are tablets, not a generic version of the CombiPatch transdermal system. A pharmacist cannot convert a patch prescription into an oral product without a new prescription, and a plan that covers the tablet has not answered whether it covers the patch.

A product can also have an NDC without being an FDA-approved generic equivalent. For substitution, the relevant question is whether FDA has approved a therapeutically equivalent product in the same dosage form and strength—not whether somebody found a product code or a generic-development document.

The reframe that actually helps

The absence of a generic does not guarantee an exception. It does stop the plan from honestly resolving the claim by telling you to fill a nonexistent generic CombiPatch.

If the representative says “use the generic,” ask:

“What is the exact FDA-approved transdermal product name, strength, and NDC you are referring to?”

That question forces the conversation back to a real covered product instead of a savings script copied from another drug.

Do not waste a call asking for a product that does not exist. Copy the NDC card and plan-call script →

---

Can You Use the CombiPatch Savings Card If You Have Medicare?

For a CombiPatch prescription eligible for Medicare reimbursement, no. Noven’s current offer excludes prescriptions eligible for reimbursement through Medicare, including Medicare Advantage and Part D. Its “cash-paying patient” language is not a way to combine the card with a Medicare drug claim. The terms also separately exclude Part D enrollees who are in the prescription drug coverage gap.

We opened the actual offer document, code CBP-3005-16 01/2026, on August 3, 2026.

What the current offer says	What it means for a Medicare reader
Eligible patients may pay as little as $25 for up to 12 prescriptions per year, limited to one use per month	That headline amount is not a Medicare benefit
The offer is for commercially insured and cash-paying patients	“Cash-paying” does not override the federal-program exclusion
It is not valid for prescriptions eligible for reimbursement through Medicare, Medicare Advantage, Part D, Medicaid, or another government-funded benefit	A Medicare-covered claim cannot use it
It cannot be combined with a free trial, discount card, prescription savings card, or another offer	It cannot be stacked with GoodRx, SingleCare, or a similar card
The maximum benefit is variable	Do not publish a fixed annual savings amount the manufacturer does not state
The terms still refer to Part D enrollees “in the prescription drug coverage gap”	The wording is stale; the 2026 Part D benefit has deductible, initial-coverage, and catastrophic stages—not a separate coverage-gap stage

That stale phrase is not a scandal, and it does not change the outcome. It is a small, checkable example of the problem this page is built to solve: a lot of drug-savings copy still describes a Medicare benefit that has changed.

If you already tried the coupon and it failed

You were not doing it wrong. The system applied the eligibility terms and nobody explained them.

For an unusual situation—such as Medicare enrollment without a drug benefit and a prescription you believe is not eligible for federal reimbursement—call the offer help desk at 1-833-483-2178 before relying on the card. Do not assume the phrase “cash-paying” settles eligibility.

Source: Noven — current CombiPatch Savings Offer terms.

What happens if you use a discount card instead of Part D?

Medicare says that when you use a discount card instead of your Medicare plan, the purchase does not count toward your Part D deductible or out-of-pocket maximum.

How you pay	Uses your Part D benefit?	Counts toward the Part D deductible and $2,100 threshold?
Claim processed through Part D for a covered drug	Yes	Yes, when the spending qualifies under Part D rules
Discount card used instead of the plan	No	No
Full cash price not processed through Part D at purchase	No	Not at purchase; save the receipt because the plan may later credit or reimburse an eligible claim it accepts under Part D

Translation: the cheapest fill in March can be the expensive choice by December. Compare the cash amount with the live Part D amount and the effect on your annual spending before you choose.

Before handing over a discount card, ask the pharmacy to run the Part D claim and tell you both prices. Get the exact wording to use at the counter →

Source: Medicare — help with drug costs.

---

What Does CombiPatch Cost If Your Plan Will Not Pay?

The reproducible cash and discount figures we found for one eight-patch carton ranged from $246.82 to $267.81 on August 3, 2026. The lower figure included a one-time $3 SingleCare signup bonus, and the higher figure was a Drugs.com “from” price. Neither is a Medicare price, a national average, or a promise at your pharmacy.

Direct price source	Figure for one eight-patch carton	What the figure is	Verified
Drugs.com price guide	From $267.81 for either listed strength	Published cash “from” price; not valid with insurance and not guaranteed	August 3, 2026
SingleCare	$249.82 before signup; $246.82 with a one-time $3 signup bonus for the displayed 0.05/0.14 mg/day carton	Discount-card price tied to the selected prescription and displayed location context; not insurance	August 3, 2026

A search-result price is not a promise. Location, pharmacy, stock, prescription details, and platform terms can change it before the claim reaches the register.

Twelve cartons is not a full continuous-schedule year

Each carton contains eight patches. The continuous-combined label schedule replaces the patch twice weekly, so one carton represents one 28-day cycle.

• 12 cartons = 96 patches = 336 days
• 13 cartons = 104 patches = 364 days

That is why multiplying a “monthly” carton price by 12 understates a continuous 52-week supply by one carton.

Do not calculate Part D coinsurance from either cash figure above. Coinsurance is applied to the plan’s negotiated amount, not a coupon platform’s displayed cash price.

One real cost reaction

“I was very surprised that it costs $135/month.”

— Mayo Clinic Connect member @seapen, November 4, 2025.

That is one person’s reported insurance price—not a Medicare estimate and not evidence about effectiveness or safety. It is useful because it shows why a retail estimate and the number one person actually pays can land nowhere near each other.

Source: Mayo Clinic Connect discussion.

---

Why Did the Pharmacy Reject Your CombiPatch Prescription?

A rejection does not automatically mean Medicare categorically excludes CombiPatch. It can mean the drug is non-formulary, the wrong benefit was billed, the exact product did not match, prior authorization or step therapy applies, a quantity limit was exceeded, the refill is early, or the pharmacy is outside the required network.

“Medicare does not cover it” is often the short version of a longer electronic message.

Get the code.

What you are told	What may be happening	What to do first
“Not covered”	Non-formulary status, wrong benefit, or no Part D claim	Confirm drug coverage, then check the exact formulary entry
“Prior authorization required”	The plan needs information before ordinary coverage	Ask for the exact criteria and route them to the prescriber
“Step therapy required”	The plan requires another covered option first	Ask which product and whether an exception is available
“Quantity exceeded”	The claim crossed a quantity limit	Compare the submitted quantity and days supply with the plan limit
“Refill too soon”	The last fill date or days supply conflicts with the new claim	Confirm the original fill and patch schedule
“Pharmacy not in network”	Network or preferred-pharmacy problem	Ask for nearby in-network and preferred options
No rejection, only a very high amount	Deductible, tier, coinsurance, coverage stage, or nonpreferred pharmacy	Ask for the claim breakdown rather than calling it a denial
Brand appears but the strength does not	Product-level mismatch	Ask the plan and pharmacy to check the exact strength and NDC

The product-level mismatch that catches CombiPatch

CombiPatch has two labeled strengths and two product codes:

Labeled delivery rate	Label NDC	Carton
Estradiol 0.05 mg/day + norethindrone acetate 0.14 mg/day	68968-0514-8	8 patches
Estradiol 0.05 mg/day + norethindrone acetate 0.25 mg/day	68968-0525-8	8 patches

If someone searched only the brand name and stopped, that is not a finished answer. Ask the representative to check your prescribed strength and your NDC.

Write these down before you hang up

• Exact rejection message or code
• Drug, strength, and NDC submitted
• Quantity and days supply
• Whether the claim went through Part D
• Formulary tier and every restriction shown
• Whether the pharmacy is preferred or merely in-network
• Whether a lower amount you saw was a cash price
• Representative’s name or identifier and call-reference number

Product source: DailyMed — current CombiPatch prescribing information.

---

What Should You Do If Your Part D Plan Denies CombiPatch?

Start with a coverage determination, not an appeal. A formulary or utilization exception is one kind of coverage determination. A redetermination—the first appeal—begins only after the plan issues an unfavorable coverage decision. Your prescriber’s supporting statement is central when medical necessity is the basis of the request.

Request	What it asks for	When it fits
Coverage determination	A formal decision about whether and how the plan will cover the drug	The starting point when the pharmacy claim or plan says no
Formulary exception	Coverage of a non-formulary drug or waiver of a utilization rule	CombiPatch is non-formulary, or PA, step therapy, or a quantity limit is blocking coverage
Tiering exception	Lower cost-sharing for an eligible drug on a nonpreferred tier	The drug is covered but the plan’s tier makes it unaffordable; availability depends on plan rules
Redetermination	Review of an unfavorable coverage determination	After the plan denies the request

The standard your prescriber has to address

CMS says a formulary-exception supporting statement must explain why covered Part D alternatives would be less effective or would cause—or be likely to cause—adverse effects, or why the plan’s dose or step requirement would be less effective or cause adverse effects.

That changes what moves the request:

• “I prefer this patch” describes a preference.
• A documented problem with a covered alternative, or a clinical reason that the alternative is expected to be less effective or cause an adverse effect, addresses the CMS standard.

Do not invent the medical justification yourself. Give the plan’s criteria and denial notice to the prescriber who knows your history.

How long the plan has

Once the plan receives the prescriber’s supporting statement for a benefit request:

• Standard exception decision: no later than 72 hours
• Expedited exception decision: no later than 24 hours when the expedited standard is accepted

If the request is denied:

• Redetermination filing deadline: generally within 65 calendar days of the coverage-determination notice
• Standard redetermination: no later than 7 calendar days
• Expedited redetermination: no later than 72 hours

An expedited request is for a situation in which waiting for the standard deadline could seriously jeopardize health or the ability to regain maximum function. It is not simply a faster lane anybody can demand.

Sources: CMS — Part D exceptions and CMS — Part D redetermination.

Your prescriber’s supporting statement—not a coupon and not a generic that does not exist—is what can move an exception. Use the coverage-determination checklist →

---

Run the CombiPatch Medicare Coverage Check

Use the exact product, plan, pharmacy, and rejection details below. The checklist itself is quick; plan and pharmacy hold times vary. This page does not ask you to enter a Medicare number or health history. Your plan may ask for your member ID when you call.

Step 1: Identify the benefit

Write down which one you have:

• Original Medicare plus a standalone Part D plan
• Medicare Advantage with drug coverage
• Employer or retiree drug coverage
• Original Medicare without drug coverage
• Not sure

If you are not sure, check your cards or call 1-800-MEDICARE before assuming the pharmacy billed the correct benefit.

Step 2: Copy the exact product

Your prescription	Copy this into your notes
CombiPatch 0.05/0.14 mg per day	NDC 68968-0514-8 · 8 patches per carton · changed twice weekly
CombiPatch 0.05/0.25 mg per day	NDC 68968-0525-8 · 8 patches per carton · changed twice weekly
Strength not known	Ask the pharmacy or prescriber before the plan search

Step 3: Search the plan’s current document

Use Medicare Plan Finder and the plan’s own current formulary. Record:

• Listed, non-formulary, or no match
• Tier
• Prior authorization
• Step therapy
• Quantity limit
• Extended-supply eligibility
• Formulary version or update date

Step 4: Call the plan with this script

“I’m calling about CombiPatch, strength [0.05/0.14 or 0.05/0.25 mg per day], NDC [68968-0514-8 or 68968-0525-8]. Is this exact product on my current formulary? What tier is it on? Does prior authorization, step therapy, or a quantity limit apply? Is [pharmacy name] preferred for my plan? What would I pay there today? If it is not covered, which FDA-approved alternatives are on my formulary, and how do my prescriber and I request a formulary, utilization, or tiering exception?”

If you have an employer or retiree plan, add:

“Is this claim paid under my Part D benefit or under additional employer coverage, and will what I pay count toward my Part D out-of-pocket spending?”

Step 5: Call the pharmacy

Ask the pharmacist to:

1. Confirm the exact NDC, quantity, and days supply submitted.
2. Run the claim through your Part D benefit.
3. Read the complete rejection message or claim explanation.
4. Confirm whether the pharmacy is preferred or only in-network.
5. Quote the live Part D amount and any separate cash-discount amount without combining them.

Step 6: Save the evidence

Record:

• Date and time
• Representative or pharmacist name
• Reference number
• Formulary date
• Exact denial or restriction
• Current Part D amount
• Cash amount, if compared
• Exception form, phone, fax, or portal instructions
• Deadline on any written denial

That single page is enough to turn “Medicare does not cover it” into a claim you can actually diagnose.

---

Could Extra Help Lower What You Pay for CombiPatch?

Yes—when CombiPatch is processed as a covered Part D prescription. In 2026, Extra Help has a $0 plan premium and $0 deductible, with participating-pharmacy copays of no more than $5.10 for a generic and $12.65 for a brand-name drug. Once qualifying drug costs reach $2,100, covered drugs cost $0 for the rest of the year.

Extra Help, also called the Low-Income Subsidy, is one of the strongest cost levers on this page. It is also the one many people rule themselves out of without checking.

The 2026 baseline figures Medicare publishes are:

2026 baseline	Individual	Married couple
Annual income limit	$23,940	$32,460
Resource limit	$18,090	$36,100

Do not treat those numbers as a final verdict. Some people qualify automatically, and Medicare says the limits can work differently in Alaska and Hawaii. Use the figures as a reason to check, not a reason to stop.

The arithmetic worth noticing is brutal: the manufacturer advertises “as little as $25” to eligible non-government-program patients, while full Extra Help caps a covered brand prescription at $12.65—and Medicare beneficiaries cannot simply use the manufacturer offer on a Medicare claim.

Checking is free. Apply for Extra Help through Social Security →

Source: Medicare — Extra Help income, resource, and 2026 copay figures.

What if the timing of the bill is the problem?

The Medicare Prescription Payment Plan lets people with Part D spread out-of-pocket costs for covered Part D drugs across monthly plan bills. Every Medicare drug plan offers it, participation is voluntary, and there is no fee to join.

Be clear-eyed about what it does:

• It does not lower the total you owe.
• It does not turn a non-formulary drug into a covered drug.
• It can help when covered drug costs hit hard early in the calendar year.

Source: Medicare — Medicare Prescription Payment Plan.

---

What FDA-Approved Alternatives Might Your Plan Cover Instead?

There is no universal Medicare-covered substitute for CombiPatch. A plan may list another FDA-approved combined product, or a prescriber may consider separately prescribed FDA-approved estrogen and progestogen products. Those options differ in molecule, route, schedule, indication, and risk; none is a pharmacy-interchangeable generic CombiPatch.

The right sequence is plan first, clinician second:

1. Ask the plan for the exact FDA-approved products it covers.
2. Record route, tier, restrictions, and pharmacy amount.
3. Take that list to the prescriber.
4. Let the prescriber decide whether any listed option fits your clinical situation.

Plan-listed category	What to verify	Why it is not an automatic swap
Another FDA-approved combined systemic product	Hormones, route, strength, schedule, tier, PA/ST/QL	Different product and prescribing instructions
FDA-approved estrogen plus a separately prescribed FDA-approved progestogen	Each product’s route, dose, timing, tier, and supply	Two prescriptions and a clinically different regimen
FDA-approved oral combination tablet	Formulary tier and clinical fit	Oral dosage form, not a transdermal generic
Compounded hormone product	Compounder, prescription, and reason an FDA-approved option does not meet the patient’s need	Not FDA-approved, not a generic, and not equivalent to CombiPatch

The compounded line this page will not cross

A compounded hormone product is not an FDA-approved generic substitute for CombiPatch. FDA does not approve compounded drugs or verify their safety, effectiveness, or quality before marketing. Compounding can meet a legitimate patient-specific need when an FDA-approved drug is not medically appropriate, but it must not be sold as a cheaper version of the same approved product.

Source: FDA — Compounding and the FDA: Questions and Answers.

We have not priced a two-prescription alternative against CombiPatch on the same date, location, pharmacy, and insurance basis. We would rather leave that number blank than manufacture a savings claim.

Take your plan’s covered-drug list into one clinical conversation instead of guessing from a formulary. Use the prescriber-question checklist above →

---

Does Your Regimen Change How Much CombiPatch You Use?

Yes. The current label describes a continuous-combined regimen using CombiPatch throughout each 28-day cycle and a continuous-sequential regimen using an estradiol-only patch for the first 14 days and CombiPatch for the final 14. The sequential regimen uses about half as many CombiPatch cartons, but it adds a second prescription and is a medical decision—not a savings trick.

Label regimen	How it runs	CombiPatch patches per 28 days	Approximate CombiPatch cartons per 364 days
Continuous combined	CombiPatch continuously, replaced every 3 to 4 days	8	13
Continuous sequential	Label-specified estradiol-only patch on days 1–14; CombiPatch on days 15–28	4	6.5, plus the estradiol-only product

Now connect that to the plan table. Both quantity limits we found—24 patches per 84 days and 8 per 28 days—match the continuous-combined schedule exactly. A sequential prescription uses a different CombiPatch quantity, while the separate estradiol-only prescription has its own formulary and supply rules.

Three things to keep firm:

1. Do not change schedules to save money. The label’s regimens require prescriber direction and have different bleeding expectations.
2. Sequential treatment is not one cheap prescription. It adds an estrogen-only product, another claim, and another supply chain.
3. Do not cut or extend patch wear on your own. The current patient instructions say to use CombiPatch exactly as directed and replace it every three to four days; they do not instruct patients to divide the system or stretch the interval.

If cost is pushing you toward improvising, say that directly to the prescriber. That is a reason to change the coverage plan or treatment plan—not a reason to silently ration a prescription.

Source: DailyMed — CombiPatch dosage and administration.

---

Can You Get a 90-Day Mail-Order Supply of CombiPatch?

Possibly, but it is plan-specific and refrigeration matters. One 2026 formulary we checked marks CombiPatch with EDS, meaning an extended 90-day supply may be dispensed through a participating retail or mail-order pharmacy. The current CombiPatch label requires refrigerated storage at 36°F to 46°F and does not give patients a six-month room-temperature storage window.

This is where generic “use mail order” advice fails if nobody checks the drug.

The current label says:

• Store CombiPatch in the refrigerator at 36°F to 46°F (2°C to 8°C).
• Keep each system in its sealed foil pouch.
• Avoid areas where extreme temperatures can occur.
• Let the patch reach room temperature before applying it.

Ask the mail pharmacy these questions before a 90-day fill

1. Is CombiPatch eligible for an extended supply under my exact plan?
2. What will I pay for 28 days versus 84 or 90 days at retail and mail order?
3. How is the refrigerated product packed and shipped?
4. What temperature-monitoring or replacement policy applies if the package arrives warm?
5. Can it be held at a pharmacy counter or carrier pickup point instead of a mailbox?
6. What should I do immediately after delivery?

A 90-day fill can be convenient and may cost less under some plans. It is not automatically cheaper, and the current label’s cold-storage requirement belongs in the decision.

Sources: DailyMed — CombiPatch storage conditions and Pharmacy Benefit Dimensions 2026 formulary.

---

Is CombiPatch in Shortage in 2026?

The current evidence does not support saying that CombiPatch is part of the 2026 estradiol-only patch shortage. ASHP’s CombiPatch-specific bulletin lists both strengths as available, but that bulletin was last updated October 17, 2024. A separate estradiol-only transdermal-system bulletin was updated July 1, 2026 and does not list CombiPatch.

ASHP bulletin	Product scope	What the bulletin says	Date
Estradiol and Norethindrone Acetate Transdermal System—CombiPatch	CombiPatch specifically	Noven has both strengths available	Last updated October 17, 2024
Estradiol Transdermal System	Estradiol-only patches	Lists affected estradiol-only products from multiple manufacturers	Updated July 1, 2026

Separate product. Separate bulletin. Different evidence.

The old update date matters. It means the CombiPatch bulletin supports the product distinction but cannot guarantee what your local wholesaler or pharmacy has today. If one pharmacy says it cannot order the product, ask whether the problem is local inventory, wholesaler availability, or a manufacturer back order, then call another in-network pharmacy before assuming CombiPatch has been discontinued.

---

Does Being Over 65 Change Anything About CombiPatch?

The CombiPatch label says too few women over 65 were included in its studies to determine whether their response differs from younger women. That is an evidence gap—not an automatic stop age and not proof of equal response. The Menopause Society says hormone therapy may continue after 65 with individualized counseling and risk assessment.

Medicare eligibility and medical suitability are separate questions:

• A formulary answers whether a plan will process a claim.
• A prescriber assesses whether the product, dose, route, and continued use fit the individual woman.
• An HRM code is a plan advisory, not a universal Medicare ban.

One plan in our spot-check attaches HRM, which that UHC document defines as a high-risk-medication advisory for people 65 and older. Treat it as a prompt for a specific prescriber conversation. It is not prior authorization, it is not an automatic rejection, and it does not prove that every plan applies the same flag.

What the current label still says

The DailyMed label available on August 3, 2026 still carries a boxed warning covering cardiovascular disorders, breast cancer, endometrial cancer, and probable dementia. FDA approved revised boxed-warning language for six other menopausal hormone therapy products in February 2026, but CombiPatch was not on FDA’s published list of those six products. Use the current CombiPatch label, not a headline about another product.

Current contraindications in the label

CombiPatch is contraindicated for women with:

• Undiagnosed abnormal genital bleeding
• Known, suspected, or past breast cancer
• Known or suspected estrogen-dependent neoplasia
• Active deep-vein thrombosis or pulmonary embolism, or a history of either
• Active arterial thromboembolic disease, such as stroke or myocardial infarction, or a history of either
• Known anaphylactic reaction, angioedema, or hypersensitivity to CombiPatch
• Known liver impairment or disease
• Known protein C, protein S, or antithrombin deficiency, or another known thrombophilic disorder
• Known or suspected pregnancy

This is the clinical safety boundary of the page: coverage does not answer whether the prescription should start or continue. Ask the prescriber how often the treatment will be reassessed and what change in symptoms, bleeding, health history, or risk would change the plan.

Sources: DailyMed — current CombiPatch label, FDA — February 2026 labeling changes to six menopausal hormone therapy products, and The Menopause Society — individualized hormone therapy after 65.

---

Can an Online Menopause Provider Fix a Medicare Coverage Problem?

No provider can force a Part D plan to cover CombiPatch. A treating prescriber can submit the supporting statement for an exception, review the plan’s FDA-approved alternatives, or reassess the regimen. The plan controls the coverage decision; the pharmacist controls the submitted claim; the prescriber supplies the clinical case.

Who can help	What that person or organization can do	What they cannot do
Part D plan	Confirm formulary status, tier, restrictions, pharmacy network, cost, and exception process	Decide which treatment is clinically right for you
Pharmacist	Read the claim response, verify the NDC and days supply, and compare the live Part D and separate cash prices	Rewrite the prescription into a different product or route
Current prescriber	Submit the clinical supporting statement and review covered FDA-approved alternatives	Guarantee that the plan approves the request
SHIP counselor	Provide free, noncommissioned Medicare counseling and help compare plan rules	Make a medical recommendation
New online or in-person clinician	Give a second clinical opinion and, when appropriate, manage a prescription	Override a plan formulary or promise Medicare reimbursement

A paid visit earns its place only when you need clinical work: a supporting statement from a treating prescriber, a review of a different FDA-approved option, or a second opinion because your current clinician is unavailable. Do not pay a provider merely to hear the plan’s formulary answer. That information is available from the plan, Medicare Plan Finder, and SHIP without an affiliate transaction.

For free Medicare counseling, use SHIP.

---

What Did The HRT Index Actually Verify?

The HRT Index Verification Standard separates official medical and regulatory facts from current commercial facts, then dates each check. For this page, we reviewed the current CombiPatch label, FDA generic records and guidance, Medicare and CMS cost and appeal rules, the manufacturer offer, five official 2026 formulary documents, two ASHP bulletins, and two live cash-price pages.

The HRT Index evaluates providers on five pillars, always in this order: clinical legitimacy, care quality, medication fit, price transparency, access. We never turn those pillars into a numeric score.

What we checked	Source type	Result and date
CombiPatch strengths, NDCs, schedules, indications, contraindications, geriatric statement, and storage	Current DailyMed prescribing information	Verified August 3, 2026; label updated February 21, 2024
FDA approval and generic status	FDA Orange Book and product-specific generic guidance	No approved ANDA generic equivalent identified as of August 3, 2026; February 2026 guidance is not approval
Part A, Part B, and Part D pathway	Medicare.gov	Verified August 2026
2026 deductible and out-of-pocket threshold	Medicare.gov	$615 maximum deductible; $2,100 covered-drug threshold
Extra Help figures	Medicare.gov	2026 income, resource, premium, deductible, and copay figures verified
Exception and appeal process	CMS	Exception standard, 24/72-hour initial deadlines, 65-day filing window, and redetermination deadlines verified
Manufacturer offer	Current Noven offer document	Terms and document code verified August 3, 2026
Five plan formulary rows	Official plan documents	Tier, restriction, quantity, EDS, and document date recorded in the table
CombiPatch and estradiol-only supply bulletins	ASHP	CombiPatch bulletin dated October 17, 2024; estradiol-only bulletin dated July 1, 2026
Cash and discount figures	Drugs.com and SingleCare	Platform-displayed figures verified August 3, 2026 and labeled by type
Patient cost language	Mayo Clinic Connect	One attributed quote verified; not used as medical evidence

What we could not verify—and will not pretend we did

• No national Medicare coverage percentage. We did not obtain a complete, representative national plan dataset.
• No universal CombiPatch copay. Member cost requires plan, pharmacy, and benefit-stage data.
• No manufacturer or plan phone verification. The page is based on published records, not undocumented calls.
• No current 2026 sample-program confirmation. An older sample form and third-party references are not enough to promise samples today.
• No guaranteed local stock. An ASHP bulletin or formulary listing does not prove that one pharmacy has a carton on its shelf.
• No universal savings figure for an alternative regimen. We did not price two clinically different prescriptions on the same plan, pharmacy, location, and date.

Why this page exists: to help a woman on Medicare find the next correct move before she pays cash, gives up on a prescription, or accepts a medication change she did not need.

Found something outdated? Tell us. We would rather fix it than defend it.

---

Common Questions About Medicare and CombiPatch

Does Medicare Part B cover CombiPatch?

Generally no, not as an ordinary retail prescription. Part B covers a limited group of outpatient drugs and usually covers medicines a patient would not normally administer herself. A self-applied CombiPatch prescription is ordinarily checked under Part D or Medicare Advantage drug coverage.

Does Medicare Part D cover both CombiPatch strengths?

It can, but there is no universal answer. Ask the plan to check the exact 0.05/0.14 or 0.05/0.25 mg-per-day product and its NDC, because formularies and claims can distinguish products at a more specific level than the brand name.

What Medicare tier is CombiPatch?

There is no single Medicare tier. In the five 2026 documents we checked, CombiPatch appeared on Tier 3 twice, Tier 4 twice, and as non-formulary once. Your current plan document is the only tier that controls your claim.

Is there a generic CombiPatch?

No FDA-approved generic equivalent was identified in the current FDA records checked through August 3, 2026. FDA’s February 2026 product-specific guidance explains how a future generic could be developed; it is not an approval or an available prescription.

Can Medicare beneficiaries use the CombiPatch savings card?

Not for a prescription eligible for Medicare reimbursement. The current offer excludes prescriptions eligible for reimbursement through Medicare, Medicare Advantage, or Part D. Its terms separately exclude Part D enrollees in the prescription drug coverage gap. The cash-payer wording is not a way to stack the offer onto a Medicare claim.

Can I use GoodRx, SingleCare, or another discount card instead of Part D?

You can choose a separate cash-discount transaction when the pharmacy accepts it, but you cannot combine that discount with the Part D claim for the same purchase. Medicare says a discount-card purchase made instead of the plan does not count toward the Part D deductible or out-of-pocket maximum.

Does CombiPatch count toward the $2,100 Part D threshold?

It can when CombiPatch is covered under Part D and the spending qualifies under Part D rules. A full-cash or discount-card purchase outside the plan does not count merely because the drug is prescription-only. Save the receipt if you later pursue Part D coverage, because an eligible claim the plan accepts or reimburses may be credited under Part D rules.

Does CombiPatch have to stay refrigerated?

Yes under the current label. Store it at 36°F to 46°F in its sealed foil pouch and avoid extreme temperatures. Let the patch reach room temperature before application. The current label does not give patients the six-month room-temperature allowance that appeared in older material.

Can I buy CombiPatch from Canada?

FDA says personal importation of foreign drugs is illegal in most circumstances, with limited enforcement discretion in defined situations, and the agency cannot assure the safety or effectiveness of medicines from foreign sources. That is the legal and supply-chain tradeoff—not a moral judgment. See FDA’s personal-importation guidance.

Can my doctor give me CombiPatch samples?

We did not verify a current 2026 sample program from a live primary source. Ask the prescriber or call Noven product information at 1-800-455-8070 before planning around samples. A sample also does not answer whether the plan will cover later cartons.

Is CombiPatch discontinued?

We found no evidence that it is discontinued. The current DailyMed record lists both strengths, and ASHP’s CombiPatch bulletin lists both as available, although that bulletin was last updated October 17, 2024. A pharmacy that cannot order it may be reporting a local or wholesaler issue rather than a national discontinuation.

What if my plan changes its formulary during the year?

For most midyear changes affecting a drug you are already taking, Medicare’s 2026 drug-coverage guide says the plan must either give written notice at least 30 days before the change takes effect or notify you at refill and provide at least a month’s supply under the prior rules. Immediate removal is permitted when FDA finds a drug unsafe or the manufacturer removes it from the market. Save the notice and request an exception when needed. New members taking a non-formulary drug may also receive a one-time transition supply during their first 90 days in the plan. See Medicare’s 2026 drug-coverage guide.

Should I switch Part D plans over CombiPatch?

Sometimes, but compare the total annual cost of every prescription, premiums, deductible, pharmacy network, and restrictions—not one CombiPatch copay in isolation. Most people can change Medicare drug coverage during Open Enrollment, October 15 through December 7, for coverage starting January 1. Other enrollment periods can apply, and people with Extra Help can change drug coverage once per calendar month. Before switching, enter every prescription and preferred pharmacy in Medicare Plan Finder and confirm the exact CombiPatch product. See Medicare’s plan-switching rules.

---

What Should You Do Next Based on What Your Plan Told You?

What you found	Your next correct move
Listed with no restriction	Confirm the live preferred-pharmacy amount, then fill it through the plan if that route makes sense
Listed with PA, step therapy, or a quantity limit	Get the exact rule and send it to the prescriber; an unmet condition stays unpaid
Listed on a high tier	Compare preferred pharmacies, Extra Help, and whether a tiering exception is available
Non-formulary	Request a coverage determination and formulary exception with the prescriber’s supporting statement
Denied after the coverage determination	File a redetermination within the notice deadline while reviewing covered FDA-approved options with the prescriber
Covered but unaffordable	Check Extra Help first, then compare the Medicare Prescription Payment Plan and live pharmacy options
Cash price is lower today	Compare the annual effect before bypassing Part D; a cash transaction does not count unless the plan later accepts or reimburses it under Part D rules
Pharmacy says unavailable	Ask whether it is a local, wholesaler, or manufacturer issue and call another in-network pharmacy

You have already done the hardest part: refusing to accept the first number or one-line rejection as the whole answer.

The rest is a plan call, a pharmacy call, and—when the plan requires it—one honest clinical conversation with your prescriber. You are allowed to ask for the exact rule, the exact price, and the exact path forward.

---

Still not sure which HRT program is right for you? Take our free 90-second matching quiz.

→ Find My HRT Path

Find My HRT Path asks about your symptoms and situation, so it collects sensitive health information. Review our consumer health data and privacy policy before you start.

---

Related guides

• Does Medicare cover HRT for menopause?
• Estradiol Patch Shortage Tracker 2026

---

Sources

1. Medicare.gov — How Part D drug plans work. Checked August 2026.
2. Medicare.gov — Outpatient prescription drug coverage. Checked August 2026.
3. Medicare.gov — 2026 Part D costs and coverage stages. Checked August 2026.
4. Medicare.gov — Help with drug costs and Extra Help. Checked August 2026.
5. Medicare.gov — Medicare Prescription Payment Plan. Checked August 2026.
6. CMS — Part D exceptions. Checked August 2026.
7. CMS — Redetermination by the Part D plan sponsor. Checked August 2026.
8. DailyMed — CombiPatch prescribing information. Read August 3, 2026; label updated February 21, 2024.
9. FDA — Orange Book. Checked August 3, 2026.
10. FDA — Estradiol/norethindrone acetate transdermal product-specific guidance. Revised February 2026; read August 3, 2026.
11. FDA — Compounding and the FDA: Questions and Answers. Checked August 2026.
12. FDA — Labeling changes to six menopausal hormone therapy products. February 12, 2026; checked August 2026.
13. FDA — Personal importation. Checked August 2026.
14. Noven — CombiPatch Savings Offer, document code CBP-3005-16 01/2026. Read August 3, 2026.
15. BCBS Michigan — 2026 group Medicare formulary. Updated August 1, 2026.
16. UnitedHealthcare — 2026 Group Medicare Advantage formulary. Last updated October 1, 2025.
17. AmeriHealth New Jersey — 2026 Medicare PPO drug list. Updated June 23, 2026.
18. Independence Blue Cross — 2026 Keystone 65 Rx / Personal Choice 65 Rx drug list. Updated June 23, 2026.
19. Pharmacy Benefit Dimensions — 2026 PDP base formulary. Updated August 1, 2026.
20. ASHP — CombiPatch shortage bulletin. Last updated October 17, 2024; read August 3, 2026.
21. ASHP — Estradiol transdermal-system shortage bulletin. Updated July 1, 2026.
22. The Menopause Society — Ongoing individualized hormone therapy appears to have no age limit. September 2024.
23. Drugs.com — CombiPatch price guide. Read August 3, 2026.
24. SingleCare — CombiPatch price page. Read August 3, 2026.
25. Mayo Clinic Connect — CombiPatch copay discussion. Post dated November 4, 2025.
26. Medicare — Your Guide to Medicare Drug Coverage. 2026 edition; checked August 2026.
27. Medicare — Switching, dropping, or rejoining drug coverage. Checked August 2026.
28. State Health Insurance Assistance Programs — SHIP. Checked August 2026.